Note: Ingredients listed on restricted chemical lists
EC/CAS
911-418-6/55965-84-9
Name of the chemical
Mixture of 5-chloro-2-methyl-2H- isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6)
Concentration
0.0015 - 0.0025
General Information
Version
4.1
Revision date
2021-11-01
Product name
NycoCard HbA1c Control
1.2.1 Relevant identified uses
Professional use
supplier name
Abbott Diagnostics Technologies AS
Manufacturer Name
Abbott Diagnostics Technologies AS
Emergency telephone
+1 703-527-3887, +1 800-424-9300, +44 191 2606182, +44 191 2606180
Icons in SDS
Company Information
company name
Abbott Diagnostics Technologies AS
e-mail address of the competent person responsible for the Safety Data Sheet
ATN_customerservice@abbott.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H317
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Adverse physicochemical, human health and environmental effects
No additional information available
Hazard pictograms
GHS07
Signal word
Warning
Contains
Mixture of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1)
Hazard statements
H317 - May cause an allergic skin reaction.
Precautionary statements
P280 - Wear protective gloves. P302+P352 - IF ON SKIN: Wash with plenty of water. P333+P313 - If skin irritation or rash occurs: Get medical advice/attention.
Other hazards which do not result in classification
Contains liquid preparations of stabilized bovine haemoglobin. Precautions should be taken as for any potentially bio hazardous material. This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605
2.1 Classification of the substance or mixture
see section 16 Adverse physicochemical, human health and environmental effects No additional information available 2.2. Label elements Labelling according to Regulation (EC) No. 1272/2008 [CLP] Hazard pictograms (CLP) : GHS07
